Npt2a抑制剂在正常及肾功能减退小鼠中促进尿磷排泄并降低血磷
该研究评估了首个口服生物可利用的Npt2a抑制剂PF-06869206在正常小鼠和5/6肾切除慢性肾脏病(CKD)小鼠模型中的效果。结果显示,Npt2a抑制呈剂量依赖性地增加尿磷、钙、钠和氯排泄,并显著降低血磷和甲状旁腺激素(PTH)水平,CKD模型中效应相似但幅度减弱。
要点
- Npt2a抑制剂可剂量依赖性地促进尿磷排泄并降低血磷。
- 正常小鼠和CKD小鼠中均观察到尿钠、氯排泄增加。
- CKD小鼠中上述效应幅度较正常小鼠减弱。
核心结论
- Npt2a抑制在正常小鼠和CKD小鼠中均引起剂量依赖性尿磷、钠、氯排泄增加,并降低血磷和PTH水平。
研究设计与样本
- 研究在正常小鼠和5/6肾切除(5/6 Nx)CKD小鼠模型中评估Npt2a抑制剂PF-06869206的剂量反应关系。
主要发现
- 正常小鼠中,Npt2a抑制导致尿磷排泄剂量依赖性增加,ED50约为21 mg/kg,同时尿钙、钠、氯排泄增加。
- 正常小鼠中,给药后3小时血磷和PTH显著下降,24小时后两者均恢复至接近基线水平。
- CKD小鼠模型中观察到相似效应,但幅度减弱。
- 正常小鼠中,尿钾排泄、尿流率和尿pH未呈剂量依赖性改变。
临床怎么用
- Npt2a抑制可能作为降低血磷的新治疗策略,但CKD中效应减弱需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The kidneys play an important role in phosphate homeostasis. Patients with CKD develop hyperphosphatemia in the later stages of the disease. Currently, treatment options are limited to dietary phosphate restriction and oral phosphate binders. The sodium-phosphate cotransporter Npt2a, which mediates a large proportion of phosphate reabsorption in the kidney, might be a good therapeutic target for new medications for hyperphosphatemia. METHODS: The authors assessed the effects of the first orally bioavailable Npt2a inhibitor (Npt2a-I) PF-06869206 in normal mice and mice that had undergone subtotal nephrectomy (5/6 Nx), a mouse model of CKD. Dose-response relationships of sodium, chloride, potassium, phosphate, and calcium excretion were assessed in response to the Npt2a inhibitor in both groups of mice. Expression and localization of Npt2a/c and levels of plasma phosphate, calcium, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF-23) were studied up to 24-hours after Npt2a-I treatment. RESULTS: In normal mice, Npt2a inhibition caused a dose-dependent increase in urinary phosphate (ED50 approximately 21 mg/kg), calcium, sodium and chloride excretion. In contrast, urinary potassium excretion, flow rate and urinary pH were not affected dose dependently. Plasma phosphate and PTH significantly decreased after 3 hours, with both returning to near baseline levels after 24 hours. Similar effects were observed in the mouse model of CKD but were reduced in magnitude. CONCLUSIONS: Npt2a inhibition causes a dose-dependent increase in phosphate, sodium and chloride excretion associated with reductions in plasma phosphate and PTH levels in normal mice and in a CKD mouse model.
引用
- Thomas L, Xue J, Murali SK, et al. Pharmacological Npt2a Inhibition Causes Phosphaturia and Reduces Plasma Phosphate in Mice with Normal and Reduced Kidney Function. J Am Soc Nephrol. 2019. PMID: 31409727. doi:10.1681/ASN.2018121250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。